ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

3M ponders drug unit sale

April 10, 2006 | APPEARED IN VOLUME 84, ISSUE 15

3M says it is exploring strategic alternatives for its global branded pharmaceuticals business and immune response modifier platform. The pharma business employs about 1,500 people worldwide. It makes and sells branded drug products related to dermatology, women's health, cardiology, and respiratory medicine. 3M says the business has been very successful but that continued success requires broad pipelines of new drugs, significant investments, and a longer term risk-reward business model than applies to most other 3M businesses.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment